Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease.
From: Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
The Journal of neuroscience : the official journal of the Society for Neuroscience
- Publish Date: Sep 2006
- ISSN: 1529-2401
- Volume: 26
- Issue: 37
- Pages: 9365-75
- Medium: Internet
- Language: English
- Citation (JAMA): McCoy Melissa K, Martinez Terina N, Ruhn Kelly A, et al. Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease.. J. Neurosci. Sep 2006;26:9365-75
Abstract
The mechanisms that trigger or contribute to loss of dopaminergic (DA) neurons in Parkinson’s disease (PD) remain unclear and controversial. Elevated levels of tumor necrosis factor (TNF) in CSF and postmortem brains of PD patients and animal models of PD implicate this proinflammatory cytokine in the pathophysiology of the disease; but a role for TNF in mediating loss of DA neurons in PD has not been clearly demonstrated. Here, we report that neutralization of soluble TNF (solTNF) in vivo with the engineered dominant-negative TNF compound XENP345 (a PEGylated version of the TNF variant A145R/I97T) reduced by 50% the retrograde nigral degeneration induced by a striatal injection of the oxidative neurotoxin 6-hydroxydopamine (6-OHDA). XENP345 was neuroprotective only when infused into the nigra, not the striatum. XENP345/6-OHDA rats displayed attenuated amphetamine-induced rotational behavior, indicating preservation of striatal dopamine levels. Similar protective effects were observed with chronic in vivo coinfusion of XENP345 with bacterial lipopolysaccharide (LPS) into the substantia nigra, confirming a role for solTNF-dependent neuroinflammation in nigral degeneration. In embryonic rat midbrain neuron/glia cell cultures exposed to LPS, even delayed administration of XENP345 prevented selective degeneration of DA neurons despite sustained microglia activation and secretion of solTNF. XENP345 also attenuated 6-OHDA-induced DA neuron toxicity in vitro. Collectively, our data demonstrate a role for TNF in vitro and in vivo in two models of PD, and raise the possibility that delaying the progressive degeneration of the nigrostriatal pathway in humans is therapeutically feasible with agents capable of blocking solTNF in early stages of PD.
Mesh Headings (Keywords): Amphetamine, Animals, Cell Death, Cells, Cultured, Coculture Techniques, Disease Models, Animal, Dopamine, Female, Gliosis, Inflammation Mediators, Motor Activity, Nerve Degeneration, Neurons, Neurotoxins, Oxidopamine, Parkinsonian Disorders, Rats, Rats, Inbred F344, Rats, Sprague-Dawley, Signal Transduction, Substantia Nigra, Treatment Outcome, Tumor Necrosis Factor-alpha
Check for Full Text / PubMed Unique Identifier (PMID): 16971520
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.